Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001062993-25-001078
Filing Date
2025-01-24
Accepted
2025-01-24 16:15:42
Documents
1
Period of Report
2025-01-22

Document Format Files

Seq Description Document Type Size
1 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES form4.html 4  
1 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES form4.xml 4 9416
  Complete submission text file 0001062993-25-001078.txt   11096
Mailing Address THREE BALA PLAZA EAST. SUITE 506 BALA CYNWYD PA 19004
Business Address THREE BALA PLAZA EAST. SUITE 506 BALA CYNWYD PA 19004 844-511-9056
Larimar Therapeutics, Inc. (Issuer) CIK: 0001374690 (see all company filings)

EIN.: 203857670 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address C/O IMPAX LABORATORIES, INC. 30831 HUNTWOOD AVENUE HAYWARD CA 94544
Business Address
BEN-MAIMON CAROLE (Reporting) CIK: 0001529611 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-36510 | Film No.: 25554406